The stock's story hinges on Goa Unit 2 ramping to meet a $220M US order book and fuel Europe's INR180cr FY27 push; momentum is steady.
Overall read
6.1/10
Priced ahead of it
The three reads · this quarter
The stock's story hinges on Goa Unit 2 ramping to meet a $220M US order book and fuel Europe's INR180cr FY27 push; momentum is steady.
Overall read
6.1/10
Priced ahead of it
The three reads · this quarter
The standing reads · change less often
Moat
Moderate edge
Key variables
4 tracked
lead: US order bookOrder book growth signals strong demand visibility and likely revenue acceleration, though execution lag may temper near-term conversion.
Walk the talk
Not enough data
as of Q1 FY270 of 1 guidance items delivered on time
Europe expansion via acquisitions (QliniQ, ABCnow) and organic setup is a key growth driver, expected to contribute INR180 cr in FY27.
Where it sits